Company profile: Crossject
1.1 - Company Overview
Company description
- Provider of needle-free drug self-injection solutions, manufacturing and marketing ZENEO, a needle-free auto-injector enabling self-administration through the skin in less than a tenth of a second. Offers core needle-free technology and conducts R&D on self-injection systems, with seven products under development primarily for emergency situations and improving emergency medicine administration.
Products and services
- Needle-free technology: Core needle-free technology enabling Crossject to develop self-injection systems, the foundation for engineering needleless drug delivery products
- Products under development: Seven emergency-focused products in development, primarily for emergency situations, extending Crossject’s needle-free self-injection systems
- ZENEO: Needle-free auto-injector engineered for self-administration of medication through the skin in less than a tenth of a second
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Crossject
NuGen Medical Devices
HQ: Canada
Website
- Description: Provider of needle-free medical delivery technologies, including InsuJet, a spring-loaded injection system for self-administration by patients and healthcare practitioners that delivers drugs through the skin, and PetJet, a device for veterinary use facilitating painless, quick treatment for pets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NuGen Medical Devices company profile →
Lexaria Bioscience
HQ: Canada
Website
- Description: Provider of patented DehydraTECH technology that improves bio-absorption, reduces onset time, and enhances delivery of lipophilic drugs across the blood-brain barrier; out-licenses this platform and operates units focused on pharmaceuticals (hypertension, antiviral, epilepsy), oral non-combusted nicotine, hemp-derived ingredients, a Health Canada licensed lab for cannabinoid and other formulations, and nutraceutical CPG applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lexaria Bioscience company profile →
Kaleo
HQ: United States
Website
- Description: Provider of specialty pharmaceutical combination drug/device products and auto-injectors, including the Aerio gas-powered auto-injector platform (single, dual container, dual chamber); AUVI-Q and ALLERJECT epinephrine devices for severe allergic reactions; Naloxone Auto-Injector 10 mg for military and chemical incident responders; Pralidoxime Chloride Auto-Injector; and a patient assistance program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kaleo company profile →
Haselmeier
HQ: Germany
Website
- Description: Provider of innovative self-injection devices, including pen injectors and other systems for self injection, featuring proprietary designs, technology and intellectual property. With over four decades of medical device experience, the company offers a world-class design and development team working in compliance with regulatory requirements.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Haselmeier company profile →
Lipocine
HQ: United States
Website
- Description: Provider of specialty pharmaceutical products, including TLANDO, an FDA-approved oral testosterone replacement therapy; LPCN 1111, an oral testosterone prodrug for hypogonadal men; LPCN 1144 and 1148, oral prodrugs of bioidentical testosterone for NASH and cirrhosis symptoms; LPCN 1107, an oral candidate to prevent recurrent preterm birth (FDA orphan drug); and LPCN 1154, an oral neurosteroid for postpartum depression.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lipocine company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Crossject
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Crossject
2.2 - Growth funds investing in similar companies to Crossject
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Crossject
4.2 - Public trading comparable groups for Crossject
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →